1. The antipsychotic chlorpromazine reduces neuroinflammation by inhibiting microglial voltage-gated potassium channels.
- Author
-
Lee HY, Lee Y, Chung C, Park SI, Shin HJ, Joe EH, Lee SJ, Kim DW, Jo SH, and Choi SY
- Subjects
- Animals, Mice, Male, Kv1.3 Potassium Channel metabolism, Kv1.3 Potassium Channel antagonists & inhibitors, Potassium Channels, Voltage-Gated metabolism, Potassium Channels, Voltage-Gated drug effects, Lipopolysaccharides pharmacology, Cytokines metabolism, Prefrontal Cortex drug effects, Prefrontal Cortex metabolism, Microglia drug effects, Microglia metabolism, Chlorpromazine pharmacology, Neuroinflammatory Diseases drug therapy, Neuroinflammatory Diseases metabolism, Antipsychotic Agents pharmacology, Mice, Inbred C57BL
- Abstract
Neuroinflammation, the result of microglial activation, is associated with the pathogenesis of a wide range of psychiatric and neurological disorders. Recently, chlorpromazine (CPZ), a dopaminergic D2 receptor antagonist and schizophrenia therapy, was proposed to exert antiinflammatory effects in the central nervous system. Here, we report that the expression of Kv1.3 channel, which is abundant in T cells, is upregulated in microglia upon infection, and that CPZ specifically inhibits these channels to reduce neuroinflammation. In the mouse medial prefrontal cortex, we show that CPZ lessens Kv1.3 channel activity and reduces proinflammatory cytokine production. In mice treated with LPS, we found that CPZ was capable of alleviating both neuroinflammation and depression-like behavior. Our findings suggest that CPZ acts as a microglial Kv1.3 channel inhibitor and neuroinflammation modulator, thereby exerting therapeutic effects in neuroinflammatory psychiatric/neurological disorders., (© 2024 The Author(s). GLIA published by Wiley Periodicals LLC.)
- Published
- 2025
- Full Text
- View/download PDF